1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO: GSK Confident In DREAMM Of Returning Blenrep To Market

DREAMM-8 Trial Is Second Trial Supporting Second-Line Use

 
• By Mary Jo Laffler

The antibody-drug conjugate, withdrawn from market for late-line use, is poised to make a return with strong results in DREAMM-7 and 8. GSK plans to refile later this year. 

Cancer cell

Having withdrawn Blenrep (belantamab mafodotin-blmf) from the US market in 2022 after failing to confirm the benefit of the antibody-drug conjugate in late-line multiple myeloma, GSK plc is preparing to refile this year for use in the second-line setting based on the DREAMM-8 trial presented 2 June at the American Society of Clinical Oncology annual meeting. The company is confident that the DREAMM-7 and 8 trials together show a “consistency of treatment effect.”

Blenrep originally received accelerated approval from the US Food and Drug Administration in 2020 for patients with relapsed/refractory multiple myeloma...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 
• By Alaric DeArment

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

More from Conferences

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.